OBJECTIVE: Previous studies of mixed aged and older adult samples with major depressive disorder (MDD) reported reduced depression response in anxious patients, but a systematic review and analysis has not been performed. Our aim was to determine if anxiety predicts antidepressant response in previously identified placebo-controlled trials of second generation antidepressants for late-life depression. METHOD: From a previous systematic review that identified ten randomized, placebo-controlled trials of community dwelling patients aged 60 or older with major depression, anxious patients were identified by a score >or=7 on the anxiety/somatization factor of the Hamilton Depression Rating Scale (HDRS). Response was defined as 50% or greater improvement on the HDRS or the Montgomery Asberg Depression Rating Scale. A meta-analysis was performed using a random effects model to calculate Odds Ratios (OR). RESULTS: Data were available from eight trials having ten drug-placebo contrasts that included 2322 anxious and 1387 non-anxious patients. The odds ratio for response to drug compared to placebo in anxious patients was 1.57 (95% CI 1.15, 2.14; z = 2.86, n = 10, p < 0.001), in non-anxious patients was 1.44 (95% CI 1.15, 1.80, z = 3.21, n = 10, p < 0.001), and did not differ between groups. Pooled response rates to drug and placebo respectively were 49.4% vs 37.4% in anxious patients and 44.2 vs 35.5% in non-anxious patients. CONCLUSIONS: In randomized, placebo-controlled trials, anxiety in late-life depression was not associated with decreased response to second generation antidepressants. (c) 2009 John Wiley & Sons, Ltd.
OBJECTIVE: Previous studies of mixed aged and older adult samples with major depressive disorder (MDD) reported reduced depression response in anxiouspatients, but a systematic review and analysis has not been performed. Our aim was to determine if anxiety predicts antidepressant response in previously identified placebo-controlled trials of second generation antidepressants for late-life depression. METHOD: From a previous systematic review that identified ten randomized, placebo-controlled trials of community dwelling patients aged 60 or older with major depression, anxiouspatients were identified by a score >or=7 on the anxiety/somatization factor of the Hamilton Depression Rating Scale (HDRS). Response was defined as 50% or greater improvement on the HDRS or the Montgomery Asberg Depression Rating Scale. A meta-analysis was performed using a random effects model to calculate Odds Ratios (OR). RESULTS: Data were available from eight trials having ten drug-placebo contrasts that included 2322 anxious and 1387 non-anxiouspatients. The odds ratio for response to drug compared to placebo in anxiouspatients was 1.57 (95% CI 1.15, 2.14; z = 2.86, n = 10, p < 0.001), in non-anxiouspatients was 1.44 (95% CI 1.15, 1.80, z = 3.21, n = 10, p < 0.001), and did not differ between groups. Pooled response rates to drug and placebo respectively were 49.4% vs 37.4% in anxiouspatients and 44.2 vs 35.5% in non-anxiouspatients. CONCLUSIONS: In randomized, placebo-controlled trials, anxiety in late-life depression was not associated with decreased response to second generation antidepressants. (c) 2009 John Wiley & Sons, Ltd.
Authors: Simon J C Davies; Benoit H Mulsant; Alastair J Flint; Anthony J Rothschild; Ellen M Whyte; Barnett S Meyers Journal: Compr Psychiatry Date: 2014-02-12 Impact factor: 3.735
Authors: John S Mulvahill; Ginger E Nicol; David Dixon; Eric J Lenze; Jordan F Karp; Charles F Reynolds; Daniel M Blumberger; Benoit H Mulsant Journal: J Am Geriatr Soc Date: 2017-12 Impact factor: 5.562
Authors: Adam Greenlee; Jordan F Karp; Mary Amanda Dew; Patricia Houck; Carmen Andreescu; Charles F Reynolds Journal: Depress Anxiety Date: 2010-05 Impact factor: 6.505
Authors: Yasmina M Saade; Ginger Nicol; Eric J Lenze; J Philip Miller; Michael Yingling; Julie Loebach Wetherell; Charles F Reynolds; Benoit H Mulsant Journal: Depress Anxiety Date: 2019-11-04 Impact factor: 6.505